Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma
Hideshi Sugiura, Hideo Mugishima(Children's Oncology Group), Masashi Ando(Tokyo National Hospital), Akira Kawai(NTT (Japan)), Toru Hiruma, Hideo Morioka, Ryohei Yokoyama(University of Miyazaki), Yasuhiro Fujiwara(Yokohama City University), Akira Ogose(Niigata University Medical and Dental Hospital), Takeshi Ishii(Chiba Cancer Center), Toshifumi Ozaki(Okayama University)
Cited by 26
Related Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2021|558
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2021|453
An antitumor promoter from Moringa oleifera Lam.
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|1999|404